https://scholars.lib.ntu.edu.tw/handle/123456789/495730
標題: | Trends in antidiabetic medical treatment from 2005 to 2014 in Taiwan | 作者: | Chu C.-H. Hsu C.-C. Lin S.-Y. LEE-MING CHUANG Liu J.-S. Tu S.-T. |
關鍵字: | Antidiabetic drugs; Diabetes; Insulin; Oral antidiabetic drugs | 公開日期: | 2019 | 出版社: | Elsevier B.V. | 卷: | 118 | 起(迄)頁: | S74-S82 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background/Purpose: Several new antidiabetic drugs have been introduced in Taiwan. However, the trends in antidiabetic treatment remain unexamined. Methods: We studied data from the Taiwan National Health Insurance Database to identify outpatient prescriptions for antidiabetic drugs from 2005 to 2014. The patterns in antidiabetic treatment and the number of different classes of antidiabetic drugs were analyzed. The proportions of prescriptions of antidiabetic monotherapy, combination therapy, or insulin therapy were further analyzed. Results: The total and mean prescriptions gradually increased during the study period. Prescription of oral antidiabetic drugs (OADs) only or insulin-only therapy decreased slightly. Prescriptions of monotherapy and dual therapy decreased, whereas those of triple or higher order combinations increased. Prescriptions of sulfonylureas (SUs) decreased, whereas those of metformin and dipeptidyl peptidease-4 (DPP4) inhibitors increased. Insulin prescriptions increased but accounted for only 13.07% of prescriptions in 2014. Among monotherapy prescriptions, SU prescriptions decreased, but metformin and DPP4 inhibitor prescriptions increased. Among dual OAD prescriptions, those including SUs decreased, and those of metformin and DPP4 inhibitors increased. Although prescriptions of the metformin–SU combination decreased, they remained the most common among all dual OAD prescriptions, followed by the metformin–DPP4 inhibitor combination. Prescriptions of human insulin decreased and those of insulin analogs increased considerably; those of basal insulin increased, and those of mixed insulin decreased. However, mixed insulin was prescribed more than basal–bolus insulin. Conclusion: Antidiabetic treatment has become complex in Taiwan. Although combination therapy would become the major treatment strategy gradually, the underuse of insulin therapy must improve. ? 2019 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067684727&doi=10.1016%2fj.jfma.2019.06.001&partnerID=40&md5=0e892950d092222980b609b9169e0cc3 https://scholars.lib.ntu.edu.tw/handle/123456789/495730 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2019.06.001 | SDG/關鍵字: | 2,4 thiazolidinedione derivative; alpha glucosidase inhibitor; antidiabetic agent; dipeptidyl peptidase IV inhibitor; human insulin; insulin; insulin derivative; metformin; oral antidiabetic agent; short acting insulin; sulfonylurea derivative; antidiabetic agent; insulin; Article; combination drug therapy; diabetes mellitus; diabetic patient; drug utilization; human; insulin treatment; major clinical study; monotherapy; national health insurance; outpatient care; prescription; Taiwan; trend study; clinical practice; diabetes mellitus; factual database; oral drug administration; outpatient; public health; Administration, Oral; Databases, Factual; Diabetes Mellitus; Drug Therapy, Combination; Drug Utilization; Humans; Hypoglycemic Agents; Insulin; National Health Programs; Outpatients; Practice Patterns, Physicians'; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。